Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SNDX

Syndax Pharmaceuticals Inc

23.61

Jul 10 • 04:00PM ET -1.23 (-4.95%)

Healthcare Biotechnology USA Mid NASD

Peers: RCUS TNGX CGON KYMR NUVL RYTM BMRN INCY KRYS AXSM

| Held by: XBI IWM VTI IWO VXF IBB SCHA VTWO FYC VHT

Scroll to Statements

Index	RUT
Market Cap	2.09B
Enterprise Value	2.09B
Income	-243.25M
Sales	217.42M
Book/sh	0.47
Cash/sh	3.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	298
IPO	Mar 03, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	9.62
P/B	50.23
P/C	5.94
P/FCF	-
EV/EBITDA	-
EV/Sales	9.59
Quick Ratio	5.06
Current Ratio	5.47
Debt/Eq	8.30
LT Debt/Eq	8.29
Option/Short	Yes / Yes

EPS (ttm)	-2.80
EPS next Y	-0.67
EPS next Q	-0.48
EPS this Y	45.95%
EPS next Y	62.33%
EPS next 5Y	-
EPS past 3/5Y	-10.26% -12.05%
Sales past 3/5Y	- 157.68%
EPS Y/Y TTM	27.68%
Sales Y/Y TTM	397.28%
EPS Q/Q	50.89%
Sales Q/Q	223.64%
Earnings	Apr 30 AMC
EPS/Sales Surpr.	21.03% -7.02%

Insider Own	8.86%
Insider Trans	-1.70%
Inst Own	106.25%
Inst Trans	0.17%
ROA	-43.70%
ROE	-189.53%
ROIC	-62.94%
Gross Margin	95.99%
Oper. Margin	-102.81%
Profit Margin	-111.88%
SMA20	13.53%
SMA50	17.59%
SMA200	18.53%
Trades

Shs Outstand	88.54M
Shs Float	80.76M
Short Float	27.01%
Short Ratio	11.47
Short Interest	21.81M
52W High	25.59 -7.74%
52W Low	9.03 161.46%
Volatility	6.44% 5.05%
ATR (14)	1.13
RSI (14)	66.01
Beta	0.38
Rel Volume	1.10
Avg Volume	1.90M
Volume	2,100,415

Perf Week	8.20%
Perf Month	33.47%
Perf Quarter	-4.64%
Perf Half Y	6.78%
Perf YTD	12.38%
Perf Year	140.43%
Perf 3Y	16.42%
Perf 5Y	41.55%
Perf 10Y	118.21%
Recom	1.08
Target Price	39.00
Prev Close	24.84
Price	23.61
Change	-4.95%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Resumed	H.C. Wainwright	Buy	$40
Sep-10-25	Resumed	Stifel	Buy	$44
Sep-04-25	Resumed	Guggenheim	Buy	$34
Aug-05-25	Reiterated	BTIG Research	Buy	$43 → $56
Jul-10-25	Initiated	Goldman	Buy	$18
Oct-24-24	Initiated	UBS	Buy	$37
Jun-28-24	Initiated	Jefferies	Buy	$37
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31

Show Previous Ratings

Jul-01-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-26 07:03AM	Syndax Showcases Revuforj (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 (GlobeNewswire)
07:00AM	Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology (GlobeNewswire)
Jun-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes (GlobeNewswire)
04:01PM	Loading…
Jun-02-26 04:01PM	Syndax Highlights Revuforj (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data (GlobeNewswire)
Jun-01-26 07:00AM	Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 (GlobeNewswire)
May-21-26 05:01PM	Syndax Announces Four Revuforj (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data (GlobeNewswire)
May-20-26 07:00AM	Syndax Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 10:31AM	Syndax Highlights 12 Revuforj (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition (GlobeNewswire)
May-06-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-26 03:18AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.83%
Apr-30-26 04:22PM	Syndax: Q1 Earnings Snapshot (Associated Press)
04:01PM	Syndax Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-26 07:00AM	Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 (GlobeNewswire)
04:01PM	Loading…
Apr-03-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-09-26 11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.) +8.20%
Mar-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-26 02:57AM	Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs (Insider Monkey)
Feb-27-26 08:30AM	Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) +5.03%
06:46AM	Syndax Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:06AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-26-26 06:00PM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-26 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-19-26 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 (GlobeNewswire)
Feb-15-26 08:05AM	Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf (MarketBeat)
Feb-14-26 01:29AM	BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact (Insider Monkey)
Feb-05-26 07:00AM	Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
04:01PM	Loading…
Feb-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-19-26 05:17PM	Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory (Insider Monkey)
Jan-12-26 07:00AM	Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:00AM	Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj (revumenib) Outside the U.S. (GlobeNewswire) +8.70%
Jan-05-26 07:00AM	Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-12-25 07:00AM	Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025 (GlobeNewswire)
Dec-08-25 06:50AM	Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum (GlobeNewswire)
Dec-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-25 07:00AM	Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-28-25 11:57AM	Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating (Insider Monkey)
Nov-16-25 10:07PM	JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains "Overweight" Rating (Insider Monkey)
Nov-11-25 01:07PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +12.79%
Nov-07-25 10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 06:03PM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +11.56%
Nov-03-25 05:35PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:08AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 (GlobeNewswire)
09:08AM	Syndax Announces Compelling Revuforj (revumenib) and Niktimvo (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 (GlobeNewswire)
Oct-31-25 09:25AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 07:00AM	Syndax Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-28-25 10:00AM	Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-25 07:00AM	Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 (GlobeNewswire)
Oct-24-25 01:58PM	Syndax Announces FDA Approval of Revuforj (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire) -7.83%
Oct-04-25 04:54PM	Syndax's Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision (Insider Monkey)
Oct-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.13%
Sep-19-25 07:00AM	Syndax's Revuforj (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire)
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -5.05%
Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.25%
Sep-01-25 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade (Zacks)
Aug-28-25 01:59PM	Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise (Zacks)
Aug-26-25 07:00AM	Syndax Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-18-25 11:42PM	Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals (Insider Monkey)
Aug-17-25 11:41PM	BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo (Insider Monkey)
Aug-14-25 09:55AM	Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? (Zacks) +9.52%
Aug-13-25 01:15AM	FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals (Insider Monkey)
Aug-06-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
11:05AM	Citi ups Syndax target, opens upside catalyst watch (TipRanks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +21.10%
04:11PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 12:00PM	All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy (Zacks) +8.15%
10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline (Zacks)
09:55AM	Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know (Zacks)
Jul-28-25 07:00AM	Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 (GlobeNewswire)
Jul-09-25 12:55AM	Syndax's Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML (Insider Monkey) +5.60%
Jul-02-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 04:01PM	Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia (GlobeNewswire)
12:45PM	Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial (Insider Monkey)
Jun-13-25 12:10PM	Syndax reports publication of revumenib data from BEAT AML trial (TipRanks)
Jun-12-25 12:02PM	Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 (GlobeNewswire)
07:00AM	Syndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 (GlobeNewswire)
Jun-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 07:00AM	Syndax Announces Participation in June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr) (GlobeNewswire) -8.93%
May-12-25 04:01PM	Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer (GlobeNewswire) -7.28%
May-09-25 09:55AM	Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? (Zacks)
May-08-25 07:00AM	Syndax Announces Participation in May Investor Conferences (GlobeNewswire) +10.21%
May-07-25 04:01PM	Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood (GlobeNewswire) -6.11%
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -21.59%
03:06AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
09:26AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

CEO & DirectorMr. Michael A. Metzger M.B.A.

CFOMr. Keith Alan Goldan CPA

Senior VPMr. Luke J. Albrecht J.D.

Chief Commercial OfficerMr. Steven Closter

MBBSDr. Nicholas A.J. Botwood B.Sc.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Metzger Michael A	Chief Executive Officer	Jul 08 '26	Option Exercise	6.38	32,375	206,552	517,218	Jul 09 04:54 PM
Metzger Michael A	Chief Executive Officer	Jul 08 '26	Sale	24.24	32,375	784,776	484,843	Jul 09 04:54 PM
MICHAEL METZGER	Director	Jul 08 '26	Proposed Sale	23.24	32,375	752,395		Jul 08 04:39 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 12 '26	Option Exercise	13.82	31,235	431,668	92,120	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 11 '26	Option Exercise	13.82	22,515	311,157	95,165	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 11 '26	Sale	18.00	34,280	617,040	60,885	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 12 '26	Sale	18.14	31,235	566,603	60,885	Jun 12 05:09 PM
Botwood Nicholas A.J.	Officer	Jun 12 '26	Proposed Sale	18.14	31,235	566,693		Jun 12 04:10 PM
Botwood Nicholas A.J.	Officer	Jun 11 '26	Proposed Sale	17.78	34,280	609,435		Jun 11 04:12 PM
Goldan Keith A.	Chief Financial Officer	Jun 01 '26	Sale	18.99	1,177	22,351	139,252	Jun 02 04:30 PM
Metzger Michael A	Chief Executive Officer	Jun 01 '26	Sale	18.99	6,847	130,025	484,843	Jun 02 04:30 PM
Goldan Keith A.	Officer	Jun 01 '26	Proposed Sale	18.99	1,177	22,352		Jun 01 03:59 PM
Metzger Michael A	Officer	Jun 01 '26	Proposed Sale	18.99	6,847	130,028		Jun 01 03:54 PM
Metzger Michael A	Chief Executive Officer	Feb 09 '26	Sale	21.03	17,159	360,819	491,690	Feb 10 09:00 AM
Goldan Keith A.	Chief Financial Officer	Feb 09 '26	Sale	21.03	3,410	71,705	140,429	Feb 10 08:59 AM
Metzger Michael A	Officer	Feb 09 '26	Proposed Sale	21.03	17,159	360,826		Feb 09 03:57 PM
Goldan Keith A.	Officer	Feb 09 '26	Proposed Sale	21.03	3,410	71,707		Feb 09 03:42 PM
Metzger Michael A	Chief Executive Officer	Feb 06 '26	Sale	20.62	7,412	152,835	508,849	Feb 06 05:54 PM
Goldan Keith A.	Chief Financial Officer	Feb 06 '26	Sale	20.62	2,082	42,931	143,839	Feb 06 05:53 PM
Metzger Michael A	Officer	Feb 06 '26	Proposed Sale	20.62	7,412	152,836		Feb 06 03:47 PM
Goldan Keith A.	Officer	Feb 06 '26	Proposed Sale	20.62	2,082	42,931		Feb 06 03:43 PM
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Option Exercise	10.90	157,307	1,714,646	455,968	Sep 08 06:45 PM
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Sale	16.41	157,307	2,582,021	298,661	Sep 08 06:45 PM
MICHAEL METZGER	Director	Sep 08 '25	Proposed Sale	17.04	157,307	2,680,511		Sep 08 04:25 PM
Podlesak Dennis	Director	Aug 14 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Sale	15.84	19,200	304,170	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Sale	15.54	19,200	298,408	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 14 '25	Sale	14.19	19,200	272,521	191,763	Aug 18 05:02 PM
DENNIS G PODLESAK	Director	Aug 18 '25	Proposed Sale	15.74	14,400	226,656		Aug 18 04:36 PM
DENNIS G PODLESAK	Director	Aug 14 '25	Proposed Sale	13.45	43,200	581,040		Aug 14 04:26 PM
Goldan Keith A.	Chief Financial Officer	Jul 16 '25	Sale	9.29	1,296	12,033	92,450	Jul 18 04:30 PM
Metzger Michael A	Chief Executive Officer	Jul 16 '25	Sale	9.29	7,534	69,953	298,661	Jul 18 04:30 PM
Goldan Keith A.	Officer	Jul 16 '25	Proposed Sale	9.29	1,296	12,034		Jul 16 03:29 PM
Metzger Michael A	Officer	Jul 16 '25	Proposed Sale	9.29	7,534	69,955		Jul 16 03:21 PM

SNDX

Syndax Pharmaceuticals Inc

Upgrade your Finviz experience